Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA)

Christina Hart,Robert Klamroth,Ulrich J. Sachs,Richard Greil,Paul N. Knoebl,Johannes Oldenburg,Wolfgang Miesbach,Christian Pfrepper,Karolin Trautmann-Grill,Isabell Pekrul,Katharina Holstein,Hermann Eichler,Carmen Weigt,Dorothea Schipp, Sonja Werwitzke, Andreas Tiede

BLOOD（2023）

引用 0|浏览0

暂无评分

摘要

Introduction: AHA is a serious autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII (FVIII). Standard of care involves immunosuppressive therapy (IST) to suppress formation of anti-FVIII autoantibodies. Recently, prophylaxis with emicizumab (EMI) has been used instead of IST to manage patients with AHA.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要